Baseline characteristics and responses to treatment with rituximab for all subjects grouped according to baseline anti-PLA2R positivity and clearance versus persistence of anti-PLA2R at 12 months after treatment
Age | Gender | Disease Duration (Months) | Serum Creatinine (mg/dl) | Creatinine Clearance (ml/min per 1.73 m2) | Baseline Anti-PLA2R | 12-Month Anti-PLA2R | Baseline Proteinuria (g/d) | Outcome (12 Months) | Outcome (24 Months) | |
---|---|---|---|---|---|---|---|---|---|---|
Group 1: anti-PLA2R positive; clearance by 12 months | ||||||||||
1 | 40 | M | 6 | 1.0 | 113 | 31,328 | 0 | 11.8 | NR | NR |
2 | 60 | F | 8 | 1.4 | 46 | 28,560 | 0 | 8.49 | PR | CR |
3 | 53 | M | 6 | 1.3 | 75 | 25,401 | 0 | 8.48 | CR | CR |
4 | 44 | M | 144 | 1.6 | 80 | 25,360 | 495e | 11.87 | NRf | PR |
5 | 52 | M | 6 | 1.5 | 74 | 25,067 | 0 | 14.69 | NRf | PR |
6 | 38 | M | 40 | 0.8 | 156 | 24,882 | 610e | 8.32 | PR | PR |
7 | 33 | M | 5 | 1.1 | 109 | 23,985 | 0 | 10.79 | CR | CR |
8 | 46 | M | 8 | 1.3 | 81 | 23,761 | 280e | 10.09 | PR | PR |
9 | 59 | M | 12 | 1.1 | 87 | 22,462 | 0 | 9.88 | PR | RL |
10 | 30 | M | 11 | 2.1 | 73 | 22,251 | 0 | 12.12 | NRf | PR |
11 | 51 | M | 24 | 2.3 | 36 | 21,325 | 0 | 16.27 | NR | PR |
12 | 47 | M | 12 | 1.8 | 49 | 20,602 | 0 | 14.23 | NRf | PR |
13 | 50 | M | 12 | 2.0 | 46 | 19,487 | 0 | 15.46 | PR | PR |
14 | 46 | M | 60 | 2.1 | 61 | 19,062 | 0 | 15.77 | PR | CR |
15 | 29 | M | 4 | 1.4 | 49 | 18,585 | 0 | 13.69 | NRf | PR |
16 | 57 | F | 4 | 0.8 | 30 | 13,506 | 660e | 8.59 | PR | CR |
17 | 64 | F | 35 | 1.0 | 89 | 9395 | 0 | 7.02 | PR | PR |
Summary | 47 ± 10 | 14:3 | 11 | 1.5 ± 0.5 | 74 ± 32 | 22,462a | 0b | 11.8 | ||
Group 2: anti-PLA2R positive; persistence at 12 monthsc | ||||||||||
18 | 42 | M | 5 | 1.0 | 119 | 31,994 | 4710 | 26.46 | NRf | PR |
19 | 60 | M | 13 | 2.6 | 40 | 31,425 | 21,190 | 20.08 | NR | ESRD |
20 | 38 | M | 10 | 1.8 | 68 | 31,082 | 16,890 | 23.44 | NR | ΔIST |
21 | 49 | M | 37 | 1.4 | 79 | 29,381 | 6361 | 8.05 | NR | ΔIST |
22 | 42 | M | 17 | 1.3 | 83 | 29,283 | 20,595 | 9.88 | NR | PR |
23 | 63 | M | 6 | 1.5 | 63 | 27,041 | 5725 | 9.09 | NR | ΔIST |
24c | 80 | M | 4 | 2.0 | 34 | 31,091 | NAc | 9.95 | ΔIST | ΔIST |
25c | 45 | M | 10 | 1.0 | 114 | 21,903 | NAc | 8.85 | PR | PR |
Summary | 49 ± 10 | 6:0 | 11.5 | 1.6 ± 0.6 | 75 ± 26 | 30,231a | 11,625b | 14.98 | ||
Group 3: anti-PLA2R negative | ||||||||||
26 | 54 | M | 96 | 2.30 | 49 | 220d | 5.73 | PR | PR | |
27 | 52 | M | 6 | 1.20 | 145 | 0d | 7.76 | PR | PR | |
28 | 37 | F | 10 | 0.90 | 102 | 0 | 8.4 | PR | CR | |
29 | 53 | M | 13 | 1.80 | 58 | 0 | 23.54 | Died | Died | |
30 | 53 | M | 7 | 1.80 | 59 | 0 | 16.59 | NR | ESRD | |
31 | 44 | F | 8 | 0.70 | 116 | 0 | 6.1 | PR | CR | |
32 | 43 | M | 108 | 1.90 | 59 | 0 | 12.76 | NR | NRf | |
33 | 29 | M | 5 | 1.00 | 126 | 0 | 11.33 | PR | CR | |
34 | 62 | M | 7 | 1.40 | 67 | 0 | 19.16 | PR | CR | |
35 | 42 | M | 12 | 1.10 | 90 | 0 | 7.81 | PR | PR | |
Summary | 47 ± 10 | 8:2 | 9 | 1.4 ± 0.5 | 87 ± 34 | 0 | 9.86 |
Baseline and 12-month anti-PLA2R levels are presented in arbitrary densitometric units. Summary data are presented as means ± standard deviation or medians when appropriate. M, male; F, female; RL, relapse; ΔIST, change in immunosuppressive therapy; NA, not available.
↵Baseline and 12 month anti-PLA2R levels were significantly lower in group 1 than in group 2 (aP = 0.001; bP < 0.001). There were no other statistically significant differences between groups 1 and 2.
↵cTwelve-month serum samples were not available for subjects 24 and 25. They are included in group 2 for the purposes of this table, but they are not included in the statistical analyses or the summary data because we were unable to determine if there was a response in anti-PLA2R or not.
↵dThese two patients had faint visible bands that fell below the detection threshold of 1000 densitometric units when assayed at 1:25.
↵eThese bands were undetectable at a 10-second exposure but were visible at longer exposures; the anti-PLA2R level was extrapolated by calculating percentage of baseline value at the 10-second and longer exposure.
↵f“Limited” response (>50% decrease from baseline proteinuria but still >3.5 g/d).